Nicholas Richardson, DO, MPH, discussed the implications of the FDA’s January draft guidance proposing MRD-negative complete response as a primary end point for accelerated approval in multiple myeloma.
Nicholas Richardson, DO, MPH
Advertisement
vice president of clinical development, Precision for Medicine, and former FDA deputy director for the Division of Hematologic Malignancies.
Articles by Nicholas Richardson, DO, MPH
The FDA proposes MRD negativity as an accelerated approval end point to speed access to novel myeloma therapies, says Nick Richardson, DO, MPH.
Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
Melatonin Use Linked to Small REM Sleep Reduction in Children
4
Opposing Sides of 340B Debate Converge on Data Clearinghouse, Patient Definition
5